Back to Search Start Over

Oncologic and survival outcomes for resectable locally-advanced HPV-related oropharyngeal cancer treated with transoral robotic surgery.

Authors :
Yver, Christina M.
Shimunov, David
Weinstein, Gregory S.
Rajasekaran, Karthik
Cannady, Steven B.
Lukens, John N.
Lin, Alexander
Swisher-McClure, Samuel
Cohen, Roger B.
Aggarwal, Charu
Bauml, Joshua M.
Loevner, Laurie A.
Newman, Jason G.
Chalian, Ara A.
Rassekh, Christopher H.
Basu, Devraj
O'Malley, Bert W.
Brody, Robert M.
O'Malley, Bert W Jr
Source :
Oral Oncology. Jul2021, Vol. 118, pN.PAG-N.PAG. 1p.
Publication Year :
2021

Abstract

<bold>Objectives: </bold>To determine whether up-front trans-oral robotic surgery (TORS) for clinically-staged locally-advanced human papillomavirus (HPV)-related oropharyngeal cancer is associated with oncologic and survival outcomes comparable to early-stage (cT1/T2) tumors.<bold>Materials and Methods: </bold>Retrospective cohort study of 628 patients with HPV-related oropharyngeal cancer who underwent up-front TORS from 2007 to 2017. Patients were stratified into two cohorts based on early-stage (cT1/2) versus locally-advanced (cT3/4) tumor at presentation.<bold>Results: </bold>We identified 589 patients who presented with early-stage tumors, and 39 patients with locally-advanced tumors. Of these, 73% of patients required adjuvant radiation, and 33% required adjuvant chemoradiation. There was no significant difference in the administration of adjuvant radiation or chemoradiation between the two cohorts. Patients in the locally-advanced disease cohort were significantly more likely to have Stage II/III disease by clinical and pathologic criteria by American Joint Committee on Cancer 8th edition criteria (p < 0.001). However, there was no significant difference in 5-year overall survival (OS) or recurrence-free survival (RFS) based on Kaplan-Meier survival estimates between the two cohorts (p = 0.75, 0.6, respectively), with estimated OS of 91% at 5 years, and estimated RFS of 86% at 5 years across the study population.<bold>Conclusions: </bold>Up-front TORS offers favorable survival outcomes for appropriately selected locally-advanced cases of HPV-related oropharyngeal cancer. Furthermore, up-front TORS is comparably effective in allowing avoidance of adjuvant therapy, particularly chemotherapy, in both cT1/T2 and locally-advanced HPV-positive oropharyngeal cancer. In the absence of clear technical contraindication to surgery, cT3/T4 classification should not be considered an absolute contraindication to surgery. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
13688375
Volume :
118
Database :
Academic Search Index
Journal :
Oral Oncology
Publication Type :
Academic Journal
Accession number :
150877128
Full Text :
https://doi.org/10.1016/j.oraloncology.2021.105307